The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2009Validation of LRRK2 as a Drug Target for Treatment of Parkinson's Disease Using Antisense Technology
Objective/Rationale:
Missense mutations in leucine-rich repeat serine/threonine-protein kinase (Lrrk2) are linked/associated with dominantly inherited, late-onset Lewy body Parkinson's disease (PD)... -
Therapeutics Development Initiative, 2009Pre-clinical Development of a Parkinson's Disease Therapy Using a Glucagon-Like Peptide (GLP)-1 Receptor Agonist
Objective/Rationale:
The Glucagon-Like-Peptide-1 (GLP-1) receptor agonist, exendin-4 (exenatide injection; brand name Byetta) is an FDA-approved, first-in-class treatment for patients with Type 2... -
Therapeutics Development Initiative, 2009Distribution of a Dominant-negative Inhibitor of Tumor Necrosis Factor
Objective/Rationale:
The blood-brain barrier (BBB) allows only a small fraction of systemically administered small-molecule drugs and even fewer biopharmaceuticals developed for disorders of the... -
MJFF Research Grant, 2009Pre-clinical Knockout Models of Parkinson's Disease
Objective/Rationale:
The objective of this project will be to use Sigma’s novel CompoZr (TM) ZFN technology to genetically engineer five distinct pre-clinical models in which genes implicated in... -
Therapeutics Development Initiative, 2009Optimization of Selective Mu Opioid Receptor Antagonists for the Treatment of Levodopa-Induced Dyskinesias in Parkinson's Disease
Objective/Rationale:
In Parkinson’s disease, L-DOPA-induced dyskinesias (LID) are therapeutically limiting side effects that occur with long-term L-DOPA treatment, and their presence significantly... -
Rapid Response Innovation Awards, 2009Identification of Nurr1 Agonists for the Treatment of Parkinson's Disease
Objective/Rationale:
Nurr1 is a nuclear hormone receptor strongly implicated in the growth, maintenance, and survival of dopaminergic neurons, that represents a very promising therapeutic target for...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.